Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status-Reference-Cited by-同舟云学术

Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status

Published:2019-01-26 Issue:5 Volume:71 Page:767-771
ISSN:0163-5581
Container-title:Nutrition and Cancer
language:en
Short-container-title:Nutrition and Cancer

Author:

Fujio Takayuki¹²,Nakashima Kazuhisa¹,Naito Tateaki¹^ORCID,Kobayashi Haruki¹,Omori Shota¹,Wakuda Kazushige¹,Ono Akira¹,Kenmotsu Hirotsugu¹,Murakami Haruyasu¹,Takahashi Toshiaki¹

Affiliation:

1. Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan;

2. Department of Hematology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan

Publisher

Informa UK Limited

Subject

Cancer Research,Nutrition and Dietetics,Oncology,Medicine (miscellaneous)

Link

https://www.tandfonline.com/doi/pdf/10.1080/01635581.2018.1559941

Reference12 articles.

1. Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2

2. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594

3. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

4. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of malnutrition according to the glim criteria on the chemotherapy toxicities in patients with advanced lung cancer;Supportive Care in Cancer;2024-05-16

2. Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?;Cancers;2022-10-05

3. Highly elevated systemic inflammation is a strong independent predictor of early mortality in advanced non-small cell lung cancer;Cancer Treatment and Research Communications;2022

4. Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer;Supportive Care in Cancer;2021-09-22

5. Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer;The Journal of Medical Investigation;2021